PharmaFocus Today – Page 4 – media

Lepu Biopharmaceuticals’ combination therapy enters Europe

Recently, Lepu Bio announced that its application for a Phase II clinical trial of its investigational EGFR-targeted ADC MRG003 combined with the PD-1 monoclonal antibody Putelizumab versus monotherapy for the treatment of locally advanced head and neck squamous cell carcinoma has been approved by the European Medicines Agency, and enrollment is scheduled to start in the third quarter of 2025. It is reported that this study is the world’s first clinical study of EGFR ADC combined with PD-1 monoclonal antibody in locally advanced head and neck squamous cell carcinoma. The world’s first Head and neck squamous cell carcinoma is a type of malignant tumor with significant heterogeneity and a high tendency to recur and metastasize. About 60% of patients have progressed to the locally advanced or metastatic stage when diagnosed, and the overall 5-year survival rate is only 30%-50%. In 2022, there will be 145,000 new cases of head and ...
- Source: drugdu
- 40
- July 2, 2025
When GLP-1 attacks migraine

In the long journey of the medical field, there are always some drugs that are as dazzling as stars. Metformin, this name is mentioned repeatedly in the medical field. It has not only been in the field of diabetes treatment for decades, but also shines with multiple potential values such as cardiovascular protection and anti-aging. It can be called a model of “miracle drug”. Today, new hope is emerging. GLP-1 weight loss drugs are emerging, following the trajectory of metformin and exuding unique charm. Recently, a report in Nature magazine caused a stir. A clinical trial focused on the GLP-1 weight loss drug liraglutide and found that it had unexpected therapeutic potential for migraine. When GLP-1 attacks migraine This study on migraine, published in Nature, was led by Lanfranco Pellesi’s team at the University of Southampton in Denmark. A total of 38 patients participated, and 31 patients were finally included ...
- Source: drugdu
- 41
- July 2, 2025
Time to Rethink Antibiotics

“One of the most universally accepted beliefs around the world,” said Brad Spellberg, MD, chief medical officer at Los Angeles General Medical Center, “is that when you take antibiotics, you must complete the prescribed course — 7, 10, or 14 days — even after you start feeling better, in order to eliminate every last bacterium and prevent a future relapse.” “But that recommendation doesn’t make sense. There’s no data to support it,” Spellberg noted in a virtual lecture at the 2025 Argentine Society of Infectious Diseases Congress, held in Mar del Plata from June 12 to 14. “That’s not how antibiotics work. Every additional day you take an antibiotic increases resistance,” he emphasized. Spellberg cited two quotes from Louis Rice, MD, chair of the Department of Medicine at the Warren Alpert Medical School of Brown University, Providence, Rhode Island, and former president of the Infectious Diseases Society of America: “The ...
- Source: drugdu
- 46
- July 1, 2025
Urine-based DNA test predicts bladder cancer recurrence after immunotherapy

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment. This study analyzed utDNA from patients in the SWOG S1605 trial, who were treated with atezolizumab, an immunotherapy drug. Researchers used the UroAmp test to examine urine samples from 89 patients at the start of treatment and from 77 patients three months later. The goal was to see if utDNA could help identify which bladder cancer patients are most likely to respond to immunotherapy. “This approach could help improve patient care by guiding more effective treatments and supporting more personalized plans. It means we may be able to tailor therapy sooner, reduce unnecessary delays and help patients avoid major surgery without compromising the quality of their care.” From Robert Svatek, MD, MSCI, professor and chair of urology at the ...
- Source: drugdu
- 45
- July 1, 2025
Drugdu.com Gains Further Recognition at CPhI

On June 26, 2025, the 23rd edition of CPhI China successfully concluded after three productive days at the Shanghai New International Expo Centre. Drugdu.com, a global B2B digital trading platform specializing in the pharmaceutical industry, showcased its comprehensive capabilities and platform value in facilitating international pharmaceutical trade, attracting visitors from around the world. ▲ June 2025, CPhI China Exhibition – Constant Visitor Flow at Drugdu.com 01｜Nine Years of Growth: Earning Long-Term International Trust Founded in 2016, Drugdu.com has built a solid track record over the past nine years. The platform now serves users across more than 220 countries and regions worldwide, covering sectors such as APIs, finished formulations, health products, pharmaceutical machinery, and medical devices. Many long-standing customers visited the Drugdu booth during the exhibition to share their positive collaboration experiences and explore further international cooperation. One long-term buyer from Latin America commented: “We have found many Chinese suppliers ...
- Source: drugdu
- 113
- June 30, 2025
Nearly 30 People in England Get Rare Illness After Botox

TUESDAY, June 24, 2025 (HealthDay News) — Dozens of people in northeastern England have developed a rare and dangerous illness after receiving Botox injections, according to health officials in the U.K. At least 28 people have reported symptoms of botulism, a potentially deadly illness that attacks the nervous system, after undergoing cosmetic procedures, the U.K. Health Security Agency (UKHSA) said on June 20, CNN reported. Investigators at the agency said that “evidence so far does not suggest that the product used has been contaminated. Symptoms are being reported a few days up to four weeks after injection.” The type of botulism in the recent cases is called iatrogenic botulism, and it can result when too much Botox is injected. The agency is also investigating possible illegal sales of Botox-like products. Botulism is caused by toxins made by Clostridium botulinum bacteria, which can lead to muscle weakness and even paralysis. ...
- Source: drugdu
- 114
- June 27, 2025
Global Vaccination Efforts Stall, Leaving Millions of Children Vulnerable to Preventable Diseases

Global efforts to protect children against diseases like measles, polio and tuberculosis have stalled since 2010, leaving millions vulnerable to deadly infections LONDON (AP) — Efforts to vaccinate children globally have stalled since 2010, leaving millions vulnerable to tetanus, polio, tuberculosis and other diseases that can be easily prevented. Protection from measles in particular dropped in 100 countries between 2010 and 2019, unravelling decades of progress, including in rich countries that had previously eliminated the highly infectious disease, according to a new analysis of global vaccination trends published Tuesday in the journal Lancet. “After clean water, vaccination is the most effective intervention for protecting the health of our children,” said Helen Bedford, a professor of children’s health at University College London, who was not connected to the research. She warned there has been a small but worrying rise in the number of parents skipping vaccination for their children in recent ...
- Source: drugdu
- 119
- June 27, 2025
Hot tubs may offer greater health benefits than saunas

Hot tubs and saunas can both soothe aching muscles and provide welcome warmth, but hot tubs might offer greater health benefits. That’s the takeaway from a new study done by researchers in the Bowerman Sports Science Center at the University of Oregon, which compared the physiological effects of soaking in a hot tub to sitting in a traditional dry heat sauna or a more modern far-infrared sauna. By raising core body temperatures, soaking in hot water can help lower blood pressure, stimulate the immune system and, over time, improve the body’s response to heat stress. Moreover, those effects can last beyond the minutes spent directly in heat treatment. “We compared the most commonly utilized modalities of passive heating as they’re used in everyday life and studied in scientific research,” said study lead author Jessica Atencio, a doctoral student in the lab of Christopher Minson. “No studies have compared the acute ...
- Source: drugdu
- 109
- June 27, 2025
FDA Requires Updated Warning About Rare Heart Risk With COVID Shots

WASHINGTON (AP) — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The ...
- Source: drugdu
- 81
- June 27, 2025
Multitasking ctDNA Helps Guide Lymphoma Treatment

Circulating tumor DNA (ctDNA) is gaining ground as an important multitasking tool in the frontline treatment of diffuse large B-cell lymphoma (DLBCL), with key novel applications that include identifying genetic subtypes and guiding the escalation or de-escalation of chemotherapy, new research has shown. “We have demonstrated that a PET/ctDNA-guided approach in frontline DLBCL is feasible in a multicenter setting,” said first author Anastasios Stathis, MD, of the Clinic of Hematology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland, in presenting the findings at the 18th International Conference on Malignant Lymphoma (ICML) 2025 in Lugano, Switzerland. “The allocation of patients and treatment based on the combined results of PET and ctDNA is operationally successful,” he said. The findings are from the preliminary results of the phase 2 SAKK 38/19 trial, which focuses on the goal of identifying patients with key MCD genetic subtypes that are known to respond poorly to the ...
- Source: drugdu
- 102
- June 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.